期刊
THERAPEUTIC DRUG MONITORING
卷 45, 期 2, 页码 133-135出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/FTD.0000000000001062
关键词
doravirine; HIV; hemodialysis; therapeutic drug monitoring; case report
This case report reveals a significant decrease in doravirine concentration due to hemodialysis in a patient with chronic renal failure and HIV-1. Therapeutic drug monitoring is suggested in patients undergoing doravirine treatment with hemodialysis.
Background:The authors report the case of a 66-year-old male patient who was hemodialyzed 3 times per week for chronic renal failure and treated with 100 mg of doravirine once daily in combination with dolutegravir for HIV-1. No dose adjustment is required for doravirine in cases of severe renal injury, but the effect of dialysis on its exposure is poorly understood.Methods & Results:Two series of 2 samples were drawn before and after 4-hour hemodialysis and showed an average doravirine concentration decrease of 48.1 +/- 6.7%. The effects of hemodialysis were important, contrary to what was expected and has been previously reported. In addition, intraindividual variability was low. Nevertheless, because the concentrations reported were largely above the inhibitory concentration 50 (IC50), no dose adjustment was required.Conclusions:The decrease in doravirine concentration due to hemodialysis observed in this case report was quite significant. Therefore, therapeutic drug monitoring might be recommended in certain patients undergoing doravirine treatment also on hemodialysis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据